Positive News SentimentPositive NewsNASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis $3.30 -0.26 (-7.30%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$3.12 -0.18 (-5.30%) As of 07:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Personalis Stock (NASDAQ:PSNL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Personalis alerts:Sign Up Key Stats Today's Range$3.25▼$3.4050-Day Range$3.30▼$6.1252-Week Range$1.14▼$7.20Volume769,970 shsAverage Volume939,627 shsMarket Capitalization$291.27 millionP/E RatioN/ADividend YieldN/APrice Target$7.80Consensus RatingBuy Company OverviewPersonalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More… Remove Ads Personalis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScorePSNL MarketRank™: Personalis scored higher than 83% of companies evaluated by MarketBeat, and ranked 165th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 4 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.40) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.41% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently increased by 14.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.66 Percentage of Shares Shorted6.41% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently increased by 14.81%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentPersonalis has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Personalis this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Personalis to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,104.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address PSNL Stock News HeadlinesPersonalis initiated with a Buy at Craig-HallumMarch 18, 2025 | markets.businessinsider.comCraig-Hallum Initiates Coverage of Personalis (PSNL) with Buy RecommendationMarch 18, 2025 | msn.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 4, 2025 | Golden Portfolio (Ad)BTIG Reaffirms Their Buy Rating on Personalis (PSNL)March 18, 2025 | markets.businessinsider.comCraig-Hallum bullish on Personalis, initiates with a BuyMarch 17, 2025 | markets.businessinsider.comNew Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence DetectionMarch 3, 2025 | businesswire.comPersonalis Reports 2024 Growth and Strategic PartnershipsFebruary 27, 2025 | tipranks.comPersonalis sees FY25 revenue $80M-$90M, consensus $84.65MFebruary 27, 2025 | markets.businessinsider.comSee More Headlines PSNL Stock Analysis - Frequently Asked Questions How have PSNL shares performed this year? Personalis' stock was trading at $5.78 at the start of the year. Since then, PSNL stock has decreased by 42.9% and is now trading at $3.30. View the best growth stocks for 2025 here. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) announced its earnings results on Thursday, February, 27th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.09. The firm earned $16.80 million during the quarter, compared to analysts' expectations of $15.48 million. Personalis had a negative trailing twelve-month return on equity of 66.07% and a negative net margin of 104.52%. When did Personalis IPO? Personalis (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Unity Software (U) and Vuzix (VUZI). Company Calendar Last Earnings2/27/2025Today4/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:PSNL CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+136.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-104.52% Pretax Margin-104.50% Return on Equity-66.07% Return on Assets-41.34% Debt Debt-to-Equity RatioN/A Current Ratio4.68 Quick Ratio4.44 Sales & Book Value Annual Sales$84.61 million Price / Sales3.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book1.25Miscellaneous Outstanding Shares88,263,000Free Float67,751,000Market Cap$291.27 million OptionableOptionable Beta1.89 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:PSNL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.